NCT05130086撤回2 期
A Phase 2 Open-Label Study to Evaluate the Safety and Pharmacokinetics of Oral Islatravir Once-Monthly in Trans and Gender Diverse Individuals on Gender-Affirming Hormone Therapy and at Low-Risk for HIV-1 Infection
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Participants with an AE leading to discontinuation of study intervention
研究概览
简要总结
The primary objective of this study is to evaluate the safety and tolerability of Islatravir (ISL) in trans and gender diverse (TGD) participants who are receiving gender-affirming hormone therapy (GAHT) and are at low-risk for human immunodeficiency virus 1 (HIV-1) infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Is confirmed HIV-uninfected based on negative HIV-1/HIV-2 test result before allocation to study intervention.
- •Is on stable GAHT and does not intend to change therapy through Week 4 of the study.
- •Has a low-risk of HIV infection.
- •Identifies with a gender that is different from that assigned at birth.
- •A participant assigned female at birth is eligible if not pregnant or chest-feeding and is not of childbearing potential (POCBP) or: Is a POCBP and using an acceptable contraceptive method, or be abstinent from penile-vaginal intercourse with an individual capable of producing sperm (abstinent on a long term and persistent basis); a POCBP must have a negative highly sensitive pregnancy test ([urine or serum] as required by local regulations) within 24 hours before the first dose of study intervention; If a urine test cannot be confirmed as negative (e.g, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive; the investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a participant assigned female at birth with an early undetected pregnancy; contraceptive use by participant assigned female at birth should be consistent with local regulations.
排除标准
- •Has known current or chronic history of liver disease (e.g, non-alcoholic or alcoholic steatohepatitis) or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome, asymptomatic gallstones, or cholecystectomy), unless the participant has stable liver function tests and no evidence of hepatic synthetic dysfunction.
- •Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or in situ anal cancers.
- •Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time (past or current use).
- •Is currently participating in or has participated in a clinical study with an investigational compound or device, within 30 days before Day 1 through the duration of the study.
- •Is expecting to conceive or donate eggs at any time during the study.
研究组 & 干预措施
Islatravir
Experimental
60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
干预措施: Islatravir (Drug)
结局指标
主要结局
Participants with an AE leading to discontinuation of study intervention
时间窗: Up to 20 weeks
Number of participants with an AE leading to discontinuation of study intervention will be reported.
Participants with one or more adverse events (AEs)
时间窗: Up to 26 weeks
Number of participants with one or more AEs will be reported.
次要结局
- Trough concentration (Ctrough) of plasma ISL(Pre-dose on Day 1; any time on Weeks 1, 2 and 3; pre-dose on Weeks 4, 8, 12, 16, 20; any time on Week 24)
- Area Under the Curve (AUC) of plasma islatravir (ISL)(Pre-dose on Day 1; any time on Weeks 1, 2 and 3; pre-dose on Weeks 4, 8, 12, 16, 20; any time on Week 24)
- Maximum concentration (Cmax) of plasma ISL(Pre-dose on Day 1; any time on Weeks 1, 2 and 3; pre-dose on Weeks 4, 8, 12, 16, 20; any time on Week 24)
- Apparent terminal half-life (t1/2) of plasma ISL(Pre-dose on Day 1; any time on Weeks 1, 2 and 3; pre-dose on Weeks 4, 8, 12, 16, 20; any time on Week 24)
研究者
相似试验
已完成
2 期
Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)Chronic Hepatitis BNCT03180619Gilead Sciences124
已完成
1 期
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's DiseaseAlzheimer DiseaseNCT04971733Eisai Inc.8
已完成
2 期
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)Chronic Hepatitis BNCT04891770Gilead Sciences103
招募中
2 期
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)Pulmonary Arterial HypertensionNCT05587712Merck Sharp & Dohme LLC42
招募中
不适用
Gene Therapy for Severe Crigler Najjar SyndromeCrigler-Najjar SyndromeNCT03466463Genethon17